Biotech Values

[oc631]

Sofosbuvir launch reverts to a decline - bet it'll come as a surprise to some of the analysts.

Warehoused patients will create a surge of demand during the first few quarters post launch which will tail off within a year. A decline should be expected in the U.S. without much concern over growth in other developed markets internationally.